Related Experiment Video

Updated: Aug 30, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

[Cefepime: the new option of target antibiotic therapy]

Alfred Samet1, Elzbieta Czarniak, Jacek Juszczyk

  • 1Zakład Mikrobiologii Klinicznej Samodzielnego Publicznego Szpitala Klinicznego Nr 1 Akademii Medycznej w Gdańsku.

Przeglad Lekarski
|November 5, 2003
PubMed

Insights

Effective treatment of multidrug-resistant hospital infections requires early microbiological monitoring. Cefepime, a fourth-generation cephalosporin, shows significant activity against resistant pathogens, especially when combined with amikacin for Pseudomonas infections.

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Hospital-acquired infections (HAIs) pose a significant challenge due to multidrug-resistant (MDR) pathogens.
  • Inadequate antimicrobial therapy is linked to poorer patient outcomes and increased resistance development.
  • Continuous monitoring of antimicrobial resistance is crucial for effective treatment strategies.

Purpose of the Study:

  • To evaluate the efficacy of cefepime as a treatment option for HAIs.
  • To assess the role of cefepime in managing infections caused by MDR pathogens.
  • To explore the potential of cefepime in combination therapy, particularly with amikacin.

Main Methods:

  • Review of existing literature on cefepime's properties and clinical applications.
  • Analysis of cefepime's pharmacokinetic and pharmacodynamic profile.
  • Examination of studies investigating cefepime's activity against MDR bacteria like Pseudomonas, Acinetobacter, Enterobacter, and Klebsiella.

Main Results:

  • Cefepime demonstrates broad-spectrum activity and rapid bactericidal effects due to its molecular structure.
  • It is effective against many nosocomial pathogens and is one of few agents with good activity against resistant strains.
  • Combination therapy with amikacin shows promise for treating MDR Pseudomonas infections.

Conclusions:

  • Cefepime is a valuable parenteral antimicrobial agent for treating HAIs caused by MDR pathogens.
  • Its favorable properties make it a suitable option, especially when resistance is a concern.
  • Combination of cefepime with amikacin is a recommended strategy for MDR Pseudomonas infections.

Related Concept Videos

Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Antibiotic Selection01:45

Antibiotic Selection

Researchers use antibiotic resistance genes to identify bacteria that possess a plasmid containing their gene of interest. Antibiotic resistance naturally occurs when a spontaneous DNA mutation creates changes in bacterial genes that eliminate antibiotic activity. Bacteria can share these new resistance genes with their offspring and other bacteria. The overuse and misuse of antibiotics have created a public health crisis, as resistant and multi-resistant bacteria continue to develop.Antibiotic...
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...